The most commonly described variant was anti‐LGI1 encephalitis (13 studies, 139 patients), followed by anti‐GABABR (9 studies, 114 patients), and anti‐CASPR2 encephalitis (3 studies, 10 patients). This evidence concerns the gene LGI1 and viral encephalitis.